Diamyd Medical, a company that develops precision medicine therapies for Type 1 Diabetes, announced on Friday that it has added Karin Rosen, MD, PhD to its Board of Directors as an adjunct member, and to be proposed for election to the board at its next General Meeting of Shareholders.
Dr Rosen has over 20 years' experience that includes clinical research and development and building, leading and successfully introducing multiple novel medicines in the United States and globally.
She has served in dual roles as the Chief Scientific Officer and Executive Vice President of R&D at Horizon Therapeutics (acquired by Amgen). She has held the position of senior vice president, US medical affairs at GlaxoSmithKline, senior vice president, US and global medical affairs at Aimmune Therapeutics, Inc. (aquired by Nestle) and a member of the clinical development leadership team working on the Phase 2b-3/4 clinical programs and filing strategies for US. Food and Drug Administration and European Medicines Agency. She has worked as therapeutic area head, immunology, at Genentech.
Ulf Hannelius, CEO of Diamyd Medical, said: "We are thrilled to welcome Dr. Rosen to Diamyd Medical at this transformative period of the Company. Karin Rosen's extensive drug development and commercial launch experience spanning a wide variety of indications including immunology, oncology, respiratory and infectious diseases will be invaluable for Diamyd Medical."
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults